A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J.
Cancer Discov. 2013 Oct;3(10):1142-55. doi: 10.1158/2159-8290.CD-13-0094. Epub 2013 Jul 18.
Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Wappenschmidt B, Becker AA, Hauke J, Weber U, Engert S, Köhler J, Kast K, Arnold N, Rhiem K, Hahnen E, Meindl A, Schmutzler RK.
PLoS One. 2012;7(12):e50800. doi: 10.1371/journal.pone.0050800. Epub 2012 Dec 11.
Unclassified sex cord-stromal tumors of the ovary: a report of eight cases.
Simpson JL, Michael H, Roth LM.
Arch Pathol Lab Med. 1998 Jan;122(1):52-5.
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W, Foster CJR, Loomis CA, Olvera N, Dao F, Levine DA, Weinberg RA, Neel BG.
Cancer Discov. 2021 Feb;11(2):362-383. doi: 10.1158/2159-8290.CD-20-0455. Epub 2020 Nov 6.
Unclassified Mixed Germ Cell-Sex Cord-Stromal Tumor of the Ovary: An Unusual Case Report.
Saenz J, Rodriguez J, Beltran M, Medina M, Pareja R.
Cureus. 2020 Jul 23;12(7):e9350. doi: 10.7759/cureus.9350.
The Rare Gynecologic Sarcoma Study: Molecular and Clinicopathologic Results of A Project on 379 Uterine Sarcomas.
Dundr P, Hojný J, Dvořák J, Hájková N, Vránková R, Krkavcová E, Berjon A, Bizoń M, Bobiński M, Bouda J, Bui QH, Căpîlna ME, Ciccarone F, Flídrová M, Fröbe A, Grabowska K, Halaška MJ, Hausnerová J, Jedryka M, Laco J, Kalist V, Klát J, Kolníková G, Książek M, Marek R, Matěj R, Michal M, Michalová K, Ndukwe M, Němejcová K, Petróczy D, Piatnytska T, Póka R, Poprawski T, Ryś J, Sawicki W, Sharashenidze A, Stolnicu S, Stružinská I, Špůrková Z, Volodko N, Zapardiel I, Zikán M, Židlík V, Cibula D, Poncová R, Kendall Bártů M.
Lab Invest. 2025 May;105(5):104092. doi: 10.1016/j.labinv.2025.104092. Epub 2025 Feb 5.
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Bignotti E, Simeon V, Ardighieri L, Kuhn E, Marchini S, Califano D, Cecere SC, Bugatti M, Spina A, Scognamiglio G, Paracchini L, Russo D, Arenare L, Tognon G, Lorusso D, Beltrame L, D'Incalci M, Sartori E, De Censi A, Odicino F, Perrone F, Chiodini P, Pignata S.
Int J Cancer. 2025 Mar 1;156(5):1085-1096. doi: 10.1002/ijc.35203. Epub 2024 Oct 16.
Understanding germ-line mutations in BRCA1.
Szabo CI, Worley T, Monteiro AN.
Cancer Biol Ther. 2004 Jun;3(6):515-20. doi: 10.4161/cbt.3.6.841. Epub 2004 Jun 1.
Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis.
Luo H, Li S, Zhao M, Sheng B, Zhu H, Zhu X.
Oncotarget. 2017 May 30;8(22):36845-36856. doi: 10.18632/oncotarget.15982.
Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects.
Bose M, Singh MI, Frödin M, Ejlertsen B, Sørensen CS, Rossing M.
J Clin Invest. 2025 Apr 15;135(12):e181879. doi: 10.1172/JCI181879. eCollection 2025 Jun 16.
